je.st
news
Tag: merck
Merck KGaA, Darmstadt, Germany, Opens New Application Laboratory in Shanghai
2017-07-21 13:50:00| Coatings World Breaking News
Tags: germany
application
laboratory
opens
Merck KGaA, Darmstadt, Germany, and Industry Partners Create New Automotive Coating Effects
2017-06-30 16:51:00| Coatings World Breaking News
Tags: create
germany
industry
effects
Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results
2017-02-02 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Fourth-Quarter 2016 Worldwide Sales Were $10.1 Billion, a Decrease of 1 Percent, Including a 1 Percent Negative Impact from Foreign Exchange; Full-Year 2016 Worldwide Sales Were $39.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Fourth-Quarter 2016 GAAP EPS Was $0.42; Fourth-Quarter Non-GAAP EPS Was $0.89; Full-Year 2016 GAAP EPS Was $2.04; Full-Year Non-GAAP EPS Was $3.78 2017 Financial Outlook Expects Full-Year 2017 GAAP EPS to be Between $2.47 and $2.62; Expects Non-GAAP EPS to be Between $3.72 and $3.87, Including an Approximately 2 Percent Negative Impact from Foreign Exchange Anticipates Full-Year 2017 Worldwide Sales to be Between $38.6 Billion and $40.1 Billion, Including an Approximately 2 Percent Negative Impact from Foreign Exchange Advanced KEYTRUDA Development Program U.S. Food and Drug Administration (FDA) Approved KEYTRUDA for Previously Untreated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score of 50 Percent or More) Without EGFR or ALK Genomic Tumor Aberrations FDA Granted Priority Review for Three Supplemental Biologics License Applications for KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2016. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: results
financial
announces
merck
Pro Football Hall of Famer and Cancer Survivor Jim Kelly Teams Up with Merck and Leading Cancer Organizations to Launch Your Cancer Game Plan
2017-01-25 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Kelly Provides His Game Plan for Navigating Head and Neck Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Head and neck cancer survivor and Pro Football Hall of Famer Jim Kelly is sharing his personal experience as part of Your Cancer Game Plan, a new awareness campaign focused on helping people with cancer and their loved ones tackle their emotional, nutritional and communication needs. Kelly, one of the toughest quarterbacks to have played Pro Football, successfully handled the gridiron with his motto Kelly Tough a motto that took on new meaning after he was diagnosed with head and neck cancer. Language: English Contact: MerckMedia:Carmen de Gourville, (267) 664-0146orChristiana Pascale, (212) 257-6722 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Merck Announces Settlement and License Agreement Resolving KEYTRUDA (pembrolizumab) Patent Litigation
2017-01-20 22:01:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as KEYTRUDA (pembrolizumab). Language: English Contact: Merck Media: Pamela Eisele, 267-305-3558Claire Gillespie, 267-305-0932or Investors: Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: agreement
license
patent
settlement
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] next »